The View of the Turkish Thoracic Society on the Report of the GOLD 2017 Global Strategy for the Diagnosis, Management, and Prevention of COPD.

Since the Global Initiative for Obstructive Lung Disease (GOLD) published its first guidelines on chronic obstructive pulmonary disease (COPD) in 2001, much has changed till 2017. Previous versions of GOLD guidelines mentioned the forced expiratory volume in one second (FEV1)-based approach for staging and treatment modalities. Since 2011, a composite multi-dimensional approach has been introduced to cover various aspects of the disease. Unfortunately, this approach was not found to be correlated with mortality as well as the FEV1-based approach, despite the fact that it was better for estimating exacerbation rates. Although this assessment tool has been considered as a big step in personalized medicine, the system was rather complex to use in daily practice. In 2017, GOLD introduced a major revision in many aspects of the disease. This mainly includes a revised assessment tool and treatment algorithm. This new ABCD algorithm has excluded spirometry for guiding pharmacological therapy. Treatment recommendations are mainly based on symptoms and exacerbation rates. Escalation and de-escalation strategies have been proposed for the first time. The spirometric measurement has only been retained to confirm the diagnosis and lead to nonpharmacological therapies. In this report, the Turkish Thoracic Society COPD assembly aimed to summarize and give an insight to the Turkish interpretation of GOLD 2017.

Do the benefits gained using a short-term pulmonary rehabilitation program remain in COPD patients after participation?

The aim of this study was to evaluate the short-term benefits of a pulmonary rehabilitation program in chronic obstructive pulmonary disease (COPD) patients. The study was a randomized controlled trial that included 54 mild and moderate COPD patients. Patients were assigned to either an 8-week-long pulmonary rehabilitation program, which consisted of exercise plus education (rehabilitation group), or were controls. All the patients were evaluated at baseline at the completion of the 8th week of the program and one month after the completion of the pulmonary rehabilitation program using five instruments: arterial blood gas analysis, postbronchodilator pulmonary function test, 6-minute walk test (6MWT), Saint George Respiratory Questionnaire (SGRQ), and the dyspnea visual analog scale (VAS) There were no statistically significant differences in the pulmonary functions and pulmonary gas analysis between baseline, discharge (8th week), and the 12th-week visit in both groups (p > 0.05). Rehabilitation resulted in significant improvements in both the VAS and the 6MWT at the 8th week, but by the 12th week all of these improvements had deteriorated. All of the SGRQ domains improved both at the 8th and the 12th week, with a significant difference between the groups (p < 0.05). We conclude that rehabilitation resulted in improvements in exercise capacity, health status, and dyspnea. All of these benefits, however, tend to deteriorate in the first month after rehabilitation. Therefore, it is strongly recommended that all patients with COPD be kept motivated in order to continue with rehabilitation and maintain the benefits gained.

[Success of smoking cessation in patients with chronic obstructive pulmonary disease]. / Kronik obstrüktif akciger hastaligi olgularinda sigarayi birakma basarisi.

Smoking causes chronic obstructive pulmonary disease (COPD) in 15 to 20% of smokers. Smoking accelerates the annual rate of FEV(1) decline, whereas it was demonstrated that smoking cessation is the major factor that reduces this decline. The aims of this prospective study were to assess the success rate and factors affecting smoking cessation, besides, to evaluate the effect of cessation on annual FEV(1) decline. Sixty-five consecutive patients with COPD and as a control group 50 ageand sex-matched healthy smokers who were admitted to our smoking cessation clinic were enrolled in the study. Intensive behavioral therapy alone or with nicotine replacement therapy or bupropion HCL was given to both groups and success rate of smoking cessation after one year was assessed. It was shown that demographic features of the subjects and the history of COPD had no effect on success of smoking cessation. At the end of one year the rate of smoking cessation was 29% in patients with COPD and 49% in the control group (p< 0.05). All different therapy interventions had similar effects on smoking cessation. The annual FEV(1) values increased 29 mL in quitters and decreased 25 mL in patients continuing smoking (p> 0.05). In this study, we concluded that the success of smoking cessation in COPD patients admitted to the smoking cessation clinic was significantly lower than healthy smokers and annual FEV(1) decline was decreased in quitters.

Complicated parapneumonic effusion and empyema thoracis: microbiologic and therapeutic aspects.

Patients with pleural infections have a high risk of morbidity and mortality with prolonged hospitalization. The best methods for treating pleural infections remain debatable. Although the increasing drainage volume effect of streptokinase adjunctive to chest-tube, is well known, its effect on clinical outcomes like duration of hospitalization and need for further surgery, remains controversial. The aim of this study was to analyze the etiological and microbiological factors for pleural infections, and assess the effect of streptokinase adjunctive to chest tube for clinical outcomes. Charts of patients with a chest disease department discharge diagnosis of complicated parapneumonic effusion or empyema were retrospectively reviewed. Of the 107 patients (85 male), the mean age was 47.9+/-17.1 years. The most frequently shown bacteriological agent was Staphylococcus aureus. Drainage with thoracentesis was used in 44 patients (group 1); chest tube was performed in 44 patients (group 2) and intrapleural streptokinase was given after chest tube insertion in 19 patients (group 3). Mean hospitalization time in group 1 was shorter than the other two groups (P<0.05), but there was no significant difference between group 2 and 3. Our mortality rate was 8.4%. Success rates were 95.4%, 65.9% and 78.5% in groups 1, 2, and 3, respectively (P>0.05). Intrapleural streptokinase is a safe procedure but it did not effect the duration of hospitalization, mortality and success rate. Mortality remains especially high in patients with concomitant disease.

Success of a smoking cessation program among smoking relatives of patients with serious smoking-related pulmonary disorders.

The aim of the study was to investigate the success of a smoking cessation program among the smoking relatives of patients with serious smoking-related disorders and to determine whether having a relative with such a disorder influences the rate of success of the program. The relatives of patients with chronic obstructive pulmonary disease (COPD) and lung cancer who wanted to quit smoking were included in the smoking cessation program (group I, n = 34). During the same period, the same number of subjects with relatives free of any smoking-related diseases were included as a control group (group II, n = 34). Intensive behavioral therapy and motivational support was given to all subjects. Nicotine replacement therapy was administered to 10 subjects (29.4%) in group I and 14 subjects (41.2%) in group II. The subjects were evaluated in the 1st, 2nd, 4th, 8th and 12th week and subsequently every 3 months for a year in the outpatient clinic and proactive telephone interviews were performed periodically. In group I, 23.5% of subjects had a relative with COPD, 61.8% had relatives with lung cancer, and 14.7% had relatives with both COPD and lung cancer. The rate of quitting smoking was 79.4 and 73.5% on the 15th day and 41.2 and 38.2% at the end of the 1st year in groups I and II, respectively (p > 0.05). We observed that having a relative with serious smoking-related disorders did not motivate smokers to quit smoking.

Respiratory impairment due to asbestos exposure in brake-lining workers.

There is extensive evidence that exposure to asbestos causes pulmonary parenchymal fibrosis, pleural disease, and malignant neoplasm in asbestos-exposed workers. However, few data concerning brake-lining workers are available in the literature. In this study, we aimed to assess the long-term effects of chrysotile asbestos exposure on lung function and the risk of asbestos-related diseases in brake-lining workers. Seventy-four asbestos-exposed workers who processed brake-lining products and 12 unexposed office workers were offered pulmonary function tests (spirometry and transfer factor) in 1992 and 1999. In 1999, the mean duration of asbestos exposure was 10.00+/-4.07 and 11.02+/-4.81 years (7-31 years) in nonsmoking and smoking asbestos workers, respectively. Transfer factor (T(L), CO) and transfer coefficient (K(CO)) decline were significant in the 7-year follow-up in both smoking and nonsmoking asbestos workers. However, lung function indices of the control group, whom were all current smokers; were also found to be decreased, including FEF(75), T(L), CO and K(CO). We found minimal reticular changes in 10 asbestos workers who were all current smokers, they underwent high-resolution computed tomography scans of the chest and we found that they had peribronchial thickening resulting from smoking. As a conclusion, even in the absence of radiographic asbestosis, T(L), CO and K(CO) may decrease after a mean 10-year duration of exposure to asbestos in brake-lining workers and this is more noticeable with cigarette burden.

[Quality of life in COPD]. / KOAH'da yasam kalitesinin degerlendirilmesi.

Measurement of health related quality of life (HRQL) is quantification of the impact of disease on daily life and well-being in a formal and standardized manner. Chronic obstructive pulmonary disease (COPD) is essentially incurable, the therapy is directed towards minimization of symptoms, reduction of exacerbations and prevention of the decline in pulmonary functions also improvement in patients' HRQL. In COPD patients, impaired pulmonary function and limited exercise capacity may result in quality of life. As the relationship between respiratory impairment and HRQL is generally weak; it's important to evaluate HRQL in patients with COPD. In this review, general and disease specific questionnaires and assessment of COPD patients is evaluated in the light of recent literatures.

[Clinical features and diagnostic approach to sarcoidosis according to stages]. / Sarkoidozda Evrelere Göre Klinik Ozellikler ve Tanisal Yaklasim.

Seventy-seven patients with sarcoidosis followed in our department evaluated retrospectively and the study continued prospectively. Depending on the radiologic findings, 26 (33.8%) of these cases were considered to be in stage 1, 47 (61.0%) were in stage 2 and 4 (5.2%) were in stage 3. Erythema nodosum was found in 29 (37.7%) cases; 15 (51.7%) of whom were stage 1, 13 (44.8%) were stage 2 and 1 (3.4%) was stage 3. There was peripheral lymphadenopathy in 8 (10.4%) cases. Bronchoscopy was performed in 68 cases and 55 found to be normal. BAL was determined in 50 of those to whom bronchoscopy had been performed. Mean BAL lymphocyte rate was found to be 32.2% and it was 36.1% in stage 1, 31.1% in stage 2 and 22.2% in stage 3. Diagnosis of sarcoidosis was confirmed with histopathologic examination in 48 cases and with BAL and other clinical signs in the others. It was confirmed with parenchymal biopsy in 15 cases, with scalene lymph node biopsy in 8 cases, with bronchial mucosa biopsy in 5, with transcranial needle aspiration biopsy in 5, with video-assisted thoracoscopic surgery in 4, with right supraclavicular lymph node biopsy in 3 and with skin biopsy in 2 cases. Tuberculin skin test was performed in 67 cases and was found to be negative in 51 (76.1%). Serum ACE levels were checked in 11 cases and found to be high in 7 of them (63.6%) (mean: 21.9). Two of 55 cases who had neurologic examination, 3 of 60 cases who had fundoscopy were found to have pathologic findings.